7th Jul 2008 15:48
Tepnel Life Sciences plc ("the Company")
Holding in Company
The Company was informed on 3 July 2008 by AXA Investment Managers UK Limited that AXA
S.A. 25 Avenue Matignon, 75008 Paris and its group companies are interested in14,530,450 ordinary shares in the Company ("Ordinary Shares") representing 6.31% of the issued share capital of the Company. These shares are represented by indirect holdings held by the following:
|
Name of Fund |
Number of Shares |
% of issued share capital |
|
AXA Framlington |
12,853,581 |
5.58 |
|
AWF Framlington Health |
1,676,869 |
0.73 |
For further information:
Tepnel Life Sciences plc
Ben Matzilevich, Chief Executive Officer
Michael Slater, Group Finance Director
Tel: 0161 946 2200
Capital MS&L
Mary Clark or Joanna Whineray
Tel: +44 20 7307 5330
Seymour Pierce Limited
Mark Percy
Tel: +44 20 7107 8000
Notes to Editors:
About Tepnel Life Sciences plc
Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences products and services Group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with over 200 employees. Tepnel provides test kits, reagents and services to two highly synergistic markets, these being Molecular Diagnostics and Biomedical Research. The Company's strategy has been to identify high growth niche opportunities within these multi-billion pound markets. Tepnel focuses on these niche operations with internally developed products, patents, expertise and know-how as well as strategic acquisitions, to develop a leadership position within these
Related Shares:
TED.L